Tenecteplase improved functional outcomes without added safety risk in selected basilar artery occlusion stroke treated up to 24 hours after onset in the TRACE-5 trial.

An individual patient-level meta-analysis shows that tenecteplase, a next-generation thrombolytic, is at least as effective as alteplase for acute stroke — and may be superior.

Making the switch from alteplase to tenecteplase for stroke thrombolysis can be done successfully when the appropriate preparations are taken, and it may improve patient outcomes, the experience of a ...

Please provide your email address to receive an email when new articles are posted on . Treatment with tenecteplase in an Australian mobile stroke unit was safe and resulted in improved outcomes ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase seems to ...

PHOENIX -- Selected stroke patients did not benefit clinically from having the window of tenecteplase therapy extended beyond the first few hours of stroke onset, the randomized TIMELESS trial found.

A 0.4 mg/kg dose of tenecteplase administered before endovascular thrombectomy in patients with large vessel occlusion ischemic stroke did not significantly improve cerebral reperfusion compared with ...

Islanders who have had a stroke will now be part of a worldwide drug study. Tenecteplase, a clot-busting drug, is already ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- ...